-

Kirby McInerney LLP Reminds Hims & Hers Health, Inc. (HIMS) Investors of Class Action Filing and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) securities during the period of April 29, 2025, through June 23, 2025, inclusive (“the Class Period”). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

[LEARN MORE ABOUT THE CLASS ACTION]

On April 29, 2025, Hims & Hers and Novo Nordisk announced a “long-term collaboration” under which Hims & Hers would sell Novo Nordisk’s popular weight loss drug Wegovy. On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, accusing Hims & Hers of engaging in “deceptive marketing” and the illegal “selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” On this news, the price of Hims & Hers shares declined $22.25 per share, or approximately 34%, from $64.22 per share on June 20, 2025 to $41.97 per share on June 23, 2025.

The lawsuit alleges that Hims & Hers failed to disclose to investors that: (1) the Company was engaged in the deceptive promotion and sale of illegitimate, knockoff versions of Wegovy that endangered patients; and (2) as a result, there was a substantial risk that the Company’s collaboration with Novo Nordisk would be terminated.

If you purchased or otherwise acquired Hims & Hers securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters without any cost to you.

[CONTACT FORM]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NYSE:HIMS

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

SPORTRADAR GROUP AG INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Sportradar Group AG (“Sportradar” or the “Company”) (NASDAQ:SRAD). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 22, 2026, Muddy Waters Research published a report alleging, among other things, that Sp...

NANO-X IMAGING LTD. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ:NNOX). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 20, 2026, Nano-X announced its fourth quarter 2025 financial results. Among other items, Nan...

ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have Until May 29, 2026 To Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until May 29, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this de...
Back to Newsroom